TwitterLinkedin

Contact Us

  • Biopharma Excellence
  • News & Events
    • Industry News Articles
    • Press Releases
    • Webinars
    • Events
    • Blog
    • Podcasts
  • Resource Library
    • Thought Leadership
    • Fact Flyers
    • Case Studies
    • White Papers
    • Webinars
    • Infographics
    • Video & Animation
  • Careers
    • Life at PharmaLex
    • Current Opportunities
  • Training
Top Bar
Search
PharmaLex Logo
MENUMENU
  • PharmaLex Logo
  • PharmaLex Logo
  • About UsAbout Us
    • About Us
    • Management Team
    • Corporate Social Responsibility
    • What Our Clients Say About Us
  • Our Services
    • Discovery / Non-clinical
          • Go to Discovery / Non-clinical section >>

          • Strategy and Consulting

            • Integrated Product Development
            • Market Access
            • Scientific Advice
            • Statistics and Data Sciences
            • Toxicology Services
    • Clinical Development
          • Go to Clinical Development section >>

          • Strategy and Consulting

            • Clinical Program Development
            • Scientific Advice
            • Statistics and Data Sciences
          • Regulatory Affairs

            • Clinical Trial Applications
            • Global Procedure Management
            • Health Authority / Agency Interaction
            • Regulatory Operations
          • Pharmacovigilance

            • Clinical Trial Safety Support
            • Pharmacovigilance Consulting
          • Quality

            • GxP Services
            • Interim / Contract QA
            • Quality Management Systems
            • Tech Transfer / Scale-up
    • Authorization / Approval
          • Go to Authorization / Approval section >>

          • Strategy and Consulting

            • Market Access
          • Regulatory Affairs

            • CMC Services
            • Global Procedure Management
            • Health Authority / Agency Interaction
            • Marketing and Labeling Activities
            • Regulatory Operations
            • Scientific, Regulatory and Technical Writing
            • Statistics and Data Sciences
          • Pharmacovigilance

            • EU QPPV / National QPPV
            • Pharmacovigilance Consulting
          • Quality

            • Commercialization Readiness
            • Commissioning, Qualification, and Validation (CQV)
            • GxP Services
            • Interim / Contract QA
            • PAI Readiness
    • Post-approval / Maintenance
          • Go to Post-approval / Maintenance section >>

          • Strategy and Consulting

            • Market Access
          • Regulatory Affairs

            • CMC Services
            • Global End-to-End Outsourcing
            • Global Procedure Management
            • Health Authority / Agency Interaction
            • Marketing and Labeling Activities
            • Mergers and Acquisitions (M&A) Transfers
            • Regulatory Operations
            • Toxicology Services
          • Pharmacovigilance

            • EU QPPV / National QPPV
            • ICSR (Individual Safety Case Report) Management
            • Literature Monitoring & Screening
            • Pharmacovigilance Quality & Compliance
            • Signal Management
          • Quality

            • Commissioning, Qualification, and Validation (CQV)
            • GxP Services
            • Interim / Contract QA
            • Quality Management Systems
          • Medical Affairs

            • Healthcare Compliance and Medical Approval
    • Program Management
          • Go to Program Management section >>

          • Program Management

            • Global End-to-End Outsourcing
            • Global Procedure Management
            • Integrated Product Development
            • Mergers and Acquisitions (M&A) Transfers
    • Featured Expertise
          • Industry Expertise

            • Biopharmaceuticals
            • MedTech Services
          • Service Expertise

            • ATMP / Cell and Gene Therapy
            • COVID-19 Support
            • GxP Services
            • Market Access
            • Pharmacovigilance Consulting
            • Post-Brexit Regulatory Support
            • Statistics and Data Sciences
            • SMARTPHLEX - technology-enabled services
  • Global ReachGlobal Reach
  • Contact usContact us
  • News & Events
    • Industry News Articles
    • Press Releases
    • Webinars
    • Events
    • Blog
    • Podcasts
  • Resource Library
    • Thought Leadership
    • Fact Flyers
    • Case Studies
    • White Papers
    • Webinars
    • Infographics
    • Video & Animation
  • Careers
    • Life at PharmaLex
    • Career Opportunities
  • Training
Home > News & Events > Ireland > Guidance for Preparing Standard Operating Procedures (SOPs)

Guidance for Preparing Standard Operating Procedures (SOPs)

For everyone working in the Pharmaceutical Industry, standard operating procedures (SOP) are a routine part of day to day operations.  An SOP as defined by Wikipedia is a set of step-by-step instructions compiled by an organisation to help workers carry out complex routine operations.  SOPs aim to achieve efficiency, quality output and uniformity of performance, while reducing miscommunication and failure to comply with industry regulations.

 

SOPs need to provide clear instruction to the end user on how to perform a task, and sufficient detail to allow the task to be executed in a consistent and uniform manner by all end users.  Many processes can be complex in nature and it is important to get the balance right between too little and too much detail. If there is too little detail this increases the potential for the end user to follow their own way of doing things. On the other hand, too much information and excessive detail increases the risks that the end user has difficulty understanding and following the steps on a daily basis, leading to errors and mistakes.

 

When writing or updating SOPS, remember these important points to avoid complexity:

Author & Reviewer: Ensure that the author of the procedure is the person that performs the task and/or understands it well while at the same time avoids going into excessive detail. The reviewer should ensure that the balance between too little and too much detail is assessed.

 

Ask Why: This technique helps to simplify and improve your work flow for a new process or for revising your procedures.  This can start with making a list of every single step in a work process from start to end. At each step of the SOPs carefully ask “why is this step required?”.

 

Red Line the procedure in the field: This is a great way to test if the procedure is still relevant and whether it makes sense. Use this time to take clear photos that you can add into your documents. There can be huge benefit in redlining or writing a procedure in the field and getting the process documented and recorded correctly.

 

Maintain Simplicity: Long, complex SOPs can be difficult to follow. Strive to keep your SOPs simple and easy to use while still ensuring all important steps are included. Break down complex tasks into smaller sub-steps. In general, keep your sentences as short as possible.

 

Photos/ Drawings/Flow Charts: The majority of the human brain is dedicated to processing visual information.  Make your procedures easy to understand by including photos, drawings and flow charts. Humans prefer visuals to text, so it makes sense to use more visual information to explain complicated information. Include illustrations, diagrams, flowcharts or other visual aids that can help with understanding.

 

Reduce the number of people involved in the tasks: The more people you have involved in a task, the more chance there is for mistakes. By reducing the number of people involved in a task, you can greatly improve how quickly it can be done and ensure that it’s done correctly.

 

Consider your audience: SOPs should be based on the education, experience, knowledge and abilities of the personnel who will use the SOP.

 

Test and verify SOP function: Once the SOP is drafted, test it with those individuals who will be use it routinely. Have them follow the SOP from beginning to end to ensure the information is clear, that all the required steps are included and are in the correct sequence. Also consider having someone with limited knowledge of the process test the SOP.

 

Protect what you have simplified: During the review process don’t let people put in additional steps or put back in what you’ve taken out without adequate justification. Exercise caution when updating SOPs as the corrective action or preventative action (CAPA) for deviations unless it is clearly identified through your root cause analysis.

 

Review and revise, as needed: Once the SOP has been in use for several weeks, ask for responses from those with direct experience using it. Ensure that the SOP is clear, accomplishes its purpose and is easy to read and use. Revise based on the feedback you receive.

 

Keep your SOPs up to date: Maintaining your SOPS in line with current practice and requirements is key.  Without periodic review of SOPs and regular updates, they can quickly become out-of-date. To keep this from happening.  SOPs should be reviewed at least every two to three years. Some SOPs may need to be reviewed on a more frequent basis, especially if the process they explain is updated or changes

 

A list of SOP’s required by the FDA, EU GMP and WHO for GMP activities – http://www.gmp-compliance.org/gmp-news/which-sops-are-required-by-gmp

For GDP, the HPRA have published a guidance document that includes the SOPs that are needed for compliance with GDP and details the general framework for each SOP https://www.hpra.ie/docs/default-source/publications-forms/guidance-documents/ia-g0038-guide-to-quality-system-for-general-sale-wholesale-distributors-v2.pdf?sfvrsn=14.

 

If you are interested in exploring how we can help you, please get in touch to discuss how PharmaLex Irleand can assist your organisation, contact us at +353 1 846 47 42 or contactirl@pharmalex.com.

Related posts
Key Takeaways from the PDA Europe Annex 1 Workshop
Key Takeaways from the PDA Europe Annex 1 Workshop
7th June 2022
NLS DAYS 2022
NLS DAYS 2022
September 28 - May 29th, 2022
Addressing Limitations of Sterility Testing
Addressing Limitations of Sterility Testing
9th May 2022
Are virtual audits sustainable post-pandemic?
Are virtual audits sustainable post-pandemic?
6th May 2022
Orphan Drug Designation: Securing the Significant Benefits
Orphan Drug Designation: Securing the Significant Benefits
28th March 2022
Virtual Audits: To be, or not to be, that is the question
Virtual Audits: To be, or not to be, that is the question
26th January 2022
Search
Upcoming Webinars

June 16th, 2022

Better information, better decisions for your access strategy – Inmediata powered by SmartPHLEX a new platform

2:30 PM CET

June 28th, 2022

eCTD in Australia: key steps to start a successful submission

08:30 am CET / 4:30 pm AEST

June 30th, 2022

Transforming the drug development process with an integrated strategy

03:00 PM CET

Upcoming Events

June 23rd, 2022

PDA Ireland: Data Integrity

June 19 - 23rd, 2022

DIA 2022 – Reconnect with Your Life Sciences Community Live in Chicago

Visit us at booth #1515

Categories
  • All News
  • Webinars
  • Events
Archive
Biopharma Excellence Website Image

PharmaLex Brings You Biopharma Excellence

Biopharma Excellence is a fusion of three scientific powerhouses, PharmaLex, ERA Consulting and Biopharma Excellence – all under the PharmaLex brand. This global team of scientific, regulatory and commercial professionals provide strategic product development and proactive regulatory services to developers of biopharmaceuticals, cell and gene therapies, monoclonal antibodies (MABs), vaccines and biosimilars.

Visit Website
USEFUL LINKS
  • Home
  • Contact us
  • Imprint
  • Data Protection
  • Terms and Conditions
RECENT TWEETS
PharmaLexGLOBALPharmaLex@PharmaLexGLOBAL·
8 Jun

Mark A Lane, PhD latest blog here https://lnkd.in/ejDdywz3 explores Integrated Product Development approaches to accelerate drug development.

To find out more register for our IPD webinar https://lnkd.in/eijUBJM5

#pharmadrugdevelopment
#webinar
#biopharmaceutical

COVID-19 NEWSLETTER SIGN UP

SIGN UP NOW

WHAT OUR CLIENTS SAY
  • We couldn’t have asked for a more professional, personable, knowledgeable group of Quality Experts!

    Top 10 Pharma Company, China
    Drug Safety Director
PharmaLex
©2022 PharmaLex GmbH. All rights reserved.

ISO9001:2015 LogoEnergie Audit LogoSGS Logo

Suspicious Emails

We are aware of a number of suspicious emails about recruitment in circulation purporting to be from PharmaLex. Emails sent by PharmaLex will originate from @pharmalex.com. Should you receive an email and are unsure as to its validity, please report it to contact@pharmalex.com.

Many thanks for your understanding.

The PharmaLex Team

    Please DO NOT send us event/conference information.
    We will not respond and these will be deleted immediately.






    Select your state:

    .
    If you do not wish to receive any communication from us, you may unsubscribe at any time.

    #AskTheExpert #TogetherBEYONDCOVID19





      Select your state:

      .
      You can unsubscribe at any time at data.protection@pharmalex.com

      If you do not wish to receive any communication from us, you can unsubscribe at any time at. Click here to view our Privacy Policy.

      #TogetherBEYONDCOVID19

      We closely monitor developments and updates surrounding the current outbreak of Coronavirus Disease 2019 (COVID-19) from official sources including the World Health Organisation and are following the guidance and direction of the governments and the local authorities. We are taking this situation very seriously and our number one priority is the safety and business continuity for our customers and colleagues. As ever, we will do everything we can to ensure that services are delivered within the required time and the trusted quality PharmaLex is known for